LifeMD, Inc. Facing Securities Fraud Class Action Lawsuit: Levi & Associates Handling Case

ition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The next steps for investors who suffered losses during the specified period is to request that the Court appoint them as lead plaintiffs before October 25, 2025. This request does not necessitate serving as a lead plaintiff to potentially benefit from any recovery. To delve deeper into the case, interested parties can subscribe to the Bulls & Betrayals podcast, which offers an episode dedicated to dissecting the allegations against LifeMD, Inc. This will help determine eligibility to join the lawsuit.

For investors who are part of the affected class, there is potential compensation available without having to cover any costs or fees out of pocket. Participation is free of obligations or financial burdens, making it accessible to those who qualify.

Levi & Korsinsky, with a reputable 20-year history, has successfully secured significant financial recoveries for aggrieved shareholders. The firm’s track record of winning high-stakes cases speaks to their extensive experience in representing investors in complex securities litigation matters. With a team of over 70 dedicated employees, Levi & Korsinsky is well-equipped to serve their clients efficiently and effectively. Their recognition in the ISS Securities Class Action Services’ Top 50 Report for seven consecutive years positions them as one of the leading securities litigation firms in the United States.

Contacting Levi & Korsinsky, LLP directly through Joseph E. Levi, Esq., or Ed Korsinsky, Esq., will provide investors with the support and guidance needed to navigate the legal process and potential recovery from losses incurred due to securities fraud involving LifeMD, Inc.